Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLNN NASDAQ:IMA NASDAQ:PDSB NASDAQ:SNGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLNNClene$5.32-1.7%$4.05$2.28▼$6.90$53.15M0.5788,282 shs33,033 shsIMAImageneBio$13.40-0.4%$15.49$11.65▼$23.28$53.87M0.510,775 shs2,166 shsPDSBPDS Biotechnology$1.24$1.23$0.85▼$4.29$57.83M1.15545,072 shs397,279 shsSNGXSoligenix$3.10+1.3%$2.11$1.09▼$6.23$13.30M2.0512.69 million shs254,899 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLNNClene0.00%-6.01%+52.44%+8.57%+0.95%IMAImageneBio0.00%-5.83%-22.45%-12.76%-34.70%PDSBPDS Biotechnology0.00%+4.20%+13.76%-12.06%-61.25%SNGXSoligenix0.00%-8.28%+13.14%+64.02%-11.43%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLNNClene3.6435 of 5 stars3.64.00.00.04.32.50.6IMAImageneBio3.1114 of 5 stars3.30.00.00.02.93.31.3PDSBPDS Biotechnology1.8358 of 5 stars3.53.00.00.02.50.00.0SNGXSoligenix2.2996 of 5 stars3.52.00.00.03.80.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLNNClene 3.17Buy$33.00520.30% UpsideIMAImageneBio 2.50Moderate Buy$35.50164.93% UpsidePDSBPDS Biotechnology 3.00Buy$10.00706.45% UpsideSNGXSoligenix 3.00Buy$6.0093.55% UpsideCurrent Analyst Ratings BreakdownLatest SNGX, IMA, CLNN, and PDSB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/21/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.008/18/2025CLNNCleneCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$83.00 ➝ $48.008/14/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.007/25/2025IMAImageneBioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$25.00 ➝ $23.007/18/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.007/16/2025SNGXSoligenixAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $6.007/1/2025PDSBPDS BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.006/30/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.006/11/2025PDSBPDS BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLNNClene$340K156.31N/AN/A($1.06) per share-5.02IMAImageneBio$9.16M5.88N/AN/A$31.33 per share0.43PDSBPDS BiotechnologyN/AN/AN/AN/A$0.51 per shareN/ASNGXSoligenix$120K110.83N/AN/A$1.64 per share1.89Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLNNClene-$39.40M-$3.76N/AN/AN/A-10,386.36%N/A-125.49%11/12/2025 (Estimated)IMAImageneBio-$49.23M-$7.68N/AN/AN/AN/A-23.94%-21.62%N/APDSBPDS Biotechnology-$37.61M-$0.92N/AN/AN/AN/A-184.56%-79.00%11/13/2025 (Estimated)SNGXSoligenix-$8.27M-$3.80N/AN/AN/AN/A-274.76%-129.20%11/14/2025 (Estimated)Latest SNGX, IMA, CLNN, and PDSB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025CLNNClene-$0.49-$0.78-$0.29-$0.78$0.06 million$0.03 million8/14/2025Q2 2025SNGXSoligenix-$0.79-$0.82-$0.03-$0.82N/AN/A8/13/2025Q2 2025PDSBPDS Biotechnology-$0.24-$0.21+$0.03-$0.21N/AN/A7/24/2025Q2 2025IMAImageneBio-$0.14-$0.06+$0.08-$0.06N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLNNCleneN/AN/AN/AN/AN/AIMAImageneBioN/AN/AN/AN/AN/APDSBPDS BiotechnologyN/AN/AN/AN/AN/ASNGXSoligenixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLNNCleneN/A1.581.57IMAImageneBioN/A13.5213.52PDSBPDS Biotechnology0.812.922.92SNGXSoligenixN/A1.471.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLNNClene23.28%IMAImageneBio75.00%PDSBPDS Biotechnology26.84%SNGXSoligenix3.60%Insider OwnershipCompanyInsider OwnershipCLNNClene35.30%IMAImageneBio5.94%PDSBPDS Biotechnology9.20%SNGXSoligenix3.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLNNClene1009.99 million6.46 millionOptionableIMAImageneBio704.02 million3.78 millionNot OptionablePDSBPDS Biotechnology2046.63 million42.34 millionOptionableSNGXSoligenix204.29 million4.16 millionNot OptionableSNGX, IMA, CLNN, and PDSB HeadlinesRecent News About These CompaniesSoligenix Inc. Reports Q2 2025 Earnings LossAugust 22, 2025 | msn.comCompanies Like Soligenix (NASDAQ:SNGX) Could Be Quite RiskyAugust 21, 2025 | finance.yahoo.comWhy Is Soligenix Stock Soaring On Monday?August 18, 2025 | benzinga.comSoligenix’s dusquetide granted Orphan Drug Designation in Behcet’s DiseaseAugust 18, 2025 | msn.comSoligenix Shares Surge After FDA Grants Orphan Drug StatusAugust 18, 2025 | msn.comSoligenix stock soars after FDA grants orphan drug designationAugust 18, 2025 | za.investing.comFDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study ResultsAugust 18, 2025 | prnewswire.comSoligenix Faces Nasdaq Non-Compliance NoticeAugust 16, 2025 | msn.comSOLIGENIX, INC.: Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial ResultsAugust 14, 2025 | finanznachrichten.deSoligenix receives FDA orphan designation for dusquetideAugust 14, 2025 | msn.comSoligenix Announces Recent Accomplishments And Second Quarter 2025 Financial ResultsAugust 14, 2025 | prnewswire.comSoligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL TherapyAugust 8, 2025 | finance.yahoo.comNetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin CancerAugust 8, 2025 | globenewswire.comSoligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL ...August 7, 2025 | gurufocus.comSoligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL ...August 7, 2025 | gurufocus.comSoligenix Completes Phase 2a Study for SGX945August 6, 2025 | theglobeandmail.comSoligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL SpaceAugust 5, 2025 | finance.yahoo.comLate-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic AreasAugust 4, 2025 | newswire.caSoligenix has phase IIa success in rare disease Behçet'sAugust 1, 2025 | bioworld.comBWhy Is Soligenix Stock (SNGX) Up 50% Today?August 1, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 2025Catalysts Align: Archer Beats Estimates, Delivers Aircraft to UAEBy Jeffrey Neal Johnson | August 13, 2025Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact?By Ryan Hasson | August 9, 20253 Stocks With Monopoly Power—and Minimal CompetitionBy Gabriel Osorio-Mazilli | August 10, 2025AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles DownBy Leo Miller | August 7, 2025SNGX, IMA, CLNN, and PDSB Company DescriptionsClene NASDAQ:CLNN$5.32 -0.09 (-1.66%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$5.30 -0.02 (-0.38%) As of 08/29/2025 06:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.ImageneBio NASDAQ:IMA$13.40 -0.06 (-0.45%) As of 08/29/2025 04:00 PM EasternImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.PDS Biotechnology NASDAQ:PDSB$1.24 0.00 (0.00%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.22 -0.02 (-2.02%) As of 08/29/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.Soligenix NASDAQ:SNGX$3.10 +0.04 (+1.31%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$3.08 -0.02 (-0.65%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
